Symptom improvement was not significantly associated with weight loss, dose, or treatment duration in women with lipoedema treated with tirzepatide: a retrospective cohort study of prospectively collected outcomes
- 1Department of Gynecology, Escola Paulista de Medicina, Federal University of São Paulo, Brazil
Abstract
Background: Weight loss may not reliably improve symptoms or adipose tissue abnormalities in lipoedema. Whether symptom improvement during incretin-based pharmacotherapy is associated with the magnitude of weight loss is unknown.
Methods: We retrospectively analysed prospectively collected outcomes from 49 women with clinically diagnosed lipoedema treated with tirzepatide in routine care at a specialist clinic between January 2024 and May 2026. The Lipedema Symptom Assessment Questionnaire (QuASiL; range 0–150) was completed before treatment and at the most recent follow-up (3–18 months). The primary analysis examined the association between percentage weight change and percentage symptom change.
Results: Weight change was not significantly associated with symptom change (r = 0.058, 95% confidence interval −0.23 to 0.33; p = 0.692). Baseline-adjusted analysis of covariance agreed (weight-change β = 0.03; p = 0.890). Symptom change was also not significantly associated with dose intensity or treatment duration. In contrast, weight change was associated with dose intensity (r = −0.569) and duration (r = −0.611).
Conclusions: Every participant improved by at least 30% on the QuASiL and 93.9% by at least 50%, yet no significant association was observed between symptom improvement and weight loss, dose intensity, or treatment duration, whereas weight loss showed exposure-response associations. The near-zero estimate, small sample and uniform symptom response leave a confidence interval that does not exclude small-to-moderate associations, so independence from weight loss cannot be inferred, and without a control group the improvement cannot be attributed to tirzepatide. These hypothesis-generating findings require confirmation in controlled studies with objective outcomes.
Related
- Treatment-Induced Neuropathy Presenting as Thoracic Radiculopathy and Abdominal Wall Protrusion After Marked Glycemic Improvement With Tirzepatide
- Socioeconomic deprivation and postoperative mortality: a retrospective analysis of prospectively collected data
- Prognostic significance of indocyanine green fluorescence patterns in resected hepatocellular carcinoma: a retrospective analysis of prospectively collected data.
- Preoperative HbA1c and postoperative day 1 fasting plasma glucose are associated with early glycemic improvement after transsphenoidal surgery in patients with acromegaly and preoperative dysglycemia: a retrospective cohort study.
- Revision arthroplasty is associated with significantly higher morbidity but not mortality compared with primary shoulder arthroplasty
BibTeX
@article{viana2026symptom,
title = {{Symptom improvement was not significantly associated with weight loss, dose, or treatment duration in women with lipoedema treated with tirzepatide: a retrospective cohort study of prospectively collected outcomes}},
author = {Diogo Pinto da Costa Viana and Adriana Luckow Invitti and Eduardo Schor},
journal = {Metabolism Open},
year = {2026},
month = oct,
doi = {10.1016/j.metop.2026.100518},
url = {https://doi.org/10.1016/j.metop.2026.100518},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Symptom improvement was not significantly associated with weight loss, dose, or treatment duration in women with lipoedema treated with tirzepatide: a retrospective cohort study of prospectively collected outcomes
AU - Diogo Pinto da Costa Viana
AU - Adriana Luckow Invitti
AU - Eduardo Schor
PY - 2026
DA - 2026/10/25
JO - Metabolism Open
DO - 10.1016/j.metop.2026.100518
UR - https://doi.org/10.1016/j.metop.2026.100518
AB - Background: Weight loss may not reliably improve symptoms or adipose tissue abnormalities in lipoedema. Whether symptom improvement during incretin-based pharmacotherapy is associated with the magnitude of weight loss is unknown. Methods: We retrospectively analysed prospectively collected outcomes from 49 women with clinically diagnosed lipoedema treated with tirzepatide in routine care at a specialist clinic between January 2024 and May 2026. The Lipedema Symptom Assessment Questionnaire (QuASiL; range 0–150) was completed before treatment and at the most recent follow-up (3–18 months). The primary analysis examined the association between percentage weight change and percentage symptom change. Results: Weight change was not significantly associated with symptom change (r = 0.058, 95% confidence interval −0.23 to 0.33; p = 0.692). Baseline-adjusted analysis of covariance agreed (weight-change β = 0.03; p = 0.890). Symptom change was also not significantly associated with dose intensity or treatment duration. In contrast, weight change was associated with dose intensity (r = −0.569) and duration (r = −0.611). Conclusions: Every participant improved by at least 30% on the QuASiL and 93.9% by at least 50%, yet no significant association was observed between symptom improvement and weight loss, dose intensity, or treatment duration, whereas weight loss showed exposure-response associations. The near-zero estimate, small sample and uniform symptom response leave a confidence interval that does not exclude small-to-moderate associations, so independence from weight loss cannot be inferred, and without a control group the improvement cannot be attributed to tirzepatide. These hypothesis-generating findings require confirmation in controlled studies with objective outcomes.
SN - 2589-9368
ER -